Atmo Biosciences

About:

Atmo Biosciences is an Australian digital health startup.

Website: https://atmobiosciences.com/

Twitter/X: atmobio

Top Investors: Breakthrough Victoria, Brisbane Angels, Hunter Angels, Medical Research Future Fund (MRFF), Otsuka Holdings

Description:

Atmo is a clinical stage digital health business focussed on empowering researchers, clinicians and patients with objective real-time insights into gut health and microbiome function. Atmo addresses the unmet clinical need to monitor microbiome function, allowing better diagnosis and management of personalised therapies for gastrointestinal disorders, resulting in improved gut health and wellness. The company is underpinned by a world-first ingestible gas-sensing capsule + cloud platform, which continuously measures clinically important gaseous biomarkers during transit through the gut and transmits the data wirelessly to the cloud for aggregation and analysis, to determine gut health or dysfunction, resulting in earlier relief of symptoms through personalised therapeutic approaches.

Total Funding Amount:

$11.5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Melbourne, Victoria, Australia

Founded Date:

2018-10-25

Contact Email:

info(AT)atmobiosciences.com

Founders:

Malcolm Hebblewhite

Number of Employees:

11-50

Last Funding Date:

2024-10-14

IPO Status:

Private

Industries:

© 2025 bioDAO.ai